TissueTech Receives FDA Clearance to Proceed with Phase 1 Clinical Study using Investigational New Drug TTAX03 to Treat Facet Joint Osteoarthritis Pain
TissueTech Receives FDA Clearance to Proceed with Phase 1 Clinical Study using Investigational New Drug TTAX03 to Treat Facet Joint Osteoarthritis Pain Investigators will evaluate the dosage and safety of Cryopreserved Amniotic Membrane and Cryopreserved Umbilical Cord TTAX03 for pain relief and functional improvement of facet joint osteoarthritis in the lumbosacral region News provided by Share this article Share this article MIAMI, March 8, 2021 /PRNewswire/ -- Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based produ...
Source: prnewswire.com